Introduction
Globally, an estimated 390 million new infections of dengue virus (DENV) are thought to occur each year, with approximately a third of infected individuals manifesting clinical symptoms (1) . A chimeric tetravalent DENV vaccine (CYD-TDV) developed by Sanofi-Pasteur was the first dengue vaccine candidate to be tested in large efficacy trials in Asia and Latin America. CYD-TDV comprises four yellow fever (YF) vaccine constructs in which the YF pre-membrane protein (prM) and E glycoprotein are individually replaced by the prM-E of the four DENV serotypes. Three trials have been conducted to date, all with the same immunization schedule that included three doses, six months apart, and study participants were followed for 25 months after the first dose. The initial Phase 2b trial (2,669 children in the vaccine test group and 1,333 in the control group), conducted in Thailand in 4-11-year-old children, showed that the primary estimate of efficacy was only 30.2% (95% CI −13.4 to 56.6) and was not significant (2) . A multicenter Phase 3 clinical trial was performed in 5 countries in South East Asia, involving 10,257 children aged 2-14 years (6, 851 children in the vaccine test group and 3,424 children in the control group) (3). The Latin American Phase 3 clinical trial involved 20,869 children aged 9-16 year (12,574 in the vaccine test group and 6,261 in the control group) (4) .
The analysis of the pooled data from the two Phase 3 trials showed an overall efficacy of 60.3% (54.7%
for DENV-1, 43% for DENV-2, 71.6% for DENV-3 and 76.3% for DENV-4), and also highlighted that Downloaded by [155.69. 16 .255] at 18:53 18 February 2016 4 efficacy results were higher in children aged nine and above compared with children below the age of 9(5) Across all age groups, the level of protection in baseline seronegative subjects was clearly lower than in baseline seropositive subjects, but was overall higher in older children. In subjects 9 and above, the efficacy in baseline seropositive individuals was 81.9%, and in baseline seronegatives 52.5%. In those below the age of 9, the efficacy was 70.1% in seropositives, but only 14.4% (non-significant) in seronegatives.
In addition to providing protection against each individual serotype, safety and persistence of protective immune memory over prolonged periods are key parameters that define the value of a vaccine. The findings from a 3 year follow-up study addressing the long-term safety of CYD-TDV of the two Phase 3 trials showed that the relative risk of hospitalization across all age groups was 1.04 in the Asia Pacific trial and 0.53 in the Latin America trial (5) . A higher relative risk of hospitalization for vaccine recipients below the age of 9 was evident (1.58), and for those aged 2-5 it was as high as 7.45 (5). There were no safety signals in older children: In children aged 9 and above, the relative risk was 0.57 in the Asian trial and 0.53 in the Latin American trial. In addition to this large observation-based follow-up study, a longitudinal study by Capeding et al. monitored neutralizing titers in children and adults vaccinated with CYD-TDV over a five-year period following the last immunization (6) . A marked decline in neutralizing titers was observed over time in vaccinees that did not experience a natural dengue or flavivirus infection within the Downloaded by [155.69. 16 .255] at 18:53 18 February 2016 follow-up period. While neutralizing titers measured in the blood are a useful readout of DENV immunity, the correlation between neutralizing titers and protection is still not clear (7) .
Epidemiological studies have shown that natural infection confers long-term protection against reinfection with the same (homologous) DENV serotype but not against heterologous serotypes (8) . During a repeat infection with a heterologous serotype, serotype cross-reactive DENV-specific B and T cells are rapidly activated, producing large quantities of high affinity antibodies within a few days of infection (9-11).
Antibody titers reach a nadir three to four weeks after fever onset and subside to near baseline within one year (12, 13). These rapidly declining titers represent cross-reactive antibodies, produced by short-lived B cells after infection, which gradually disappear due to their restricted biological half-life (12). In the context of immune memory, the CYD-TDV vaccine proved to be more effecacious in individuals with pre-existing immunity to DENV or Japanese encephalitis virus (JEV) (3) (4) (5) . This suggests that re-activation of specific B and T cells was an important mechanism contributing to the protective capacity of the vaccine. It is possible that protection after vaccination depends largely on cross-reactive antibodies circulating in the blood at the time of infection. In this scenario, protection would be limited to the window of time in which the titers of these antibodies remain above a protective threshold (14-16).
The aim of this study was to assess the longevity of DENV-specific antibodies and to quantify memory B 
Results

Low antibody titers five years after vaccination with CYD-TDV
A CYD-TDY safety and immunogenicity double-blind randomized trial was initially conducted in Singapore in 2009, in which 300 adults (aged > 21) were enrolled at the National University of Singapore (17) . After official unblinding of the trial, we contacted 50 participants who had received the CYD-TDV vaccine and whose contact addresses were still available. Of these 50, 23 participants consented to have blood taken for this study. In August 2014, e.g., approximately 5 years after the first vaccination, we obtained blood samples to assess DENV-specific humoral immunity. Pre-existing immunity (if known) and age of the participants are summarized in Table 1 . We have previously established three ELISAs to separately quantify plasma antibodies binding to recombinant DENV E protein, to recombinant EDIII, and to UVinactivated virus particles (UV-DENV) for each serotype (12). We employed these three assays to determine endpoint titers in the 23 vaccinee samples. As a positive control, we used a pool of three plasma samples from healthy donors seropositive for DENV-specific IgG. Compared to the positive control, endpoint titers in the vaccine samples were 10-to >200-fold lower in the UV-DENV ELISA and in Downloaded by [155.69. 16 .255] at 18:53 18 February 2016 the E protein ELISA (Fig.1A and B ). High antibody titers, which were specific for E protein, particularly for E protein of DENV-2, were only detected in samples from DV-19 and DV-20 (Fig.1B) . Antibody titers to EDIII were comparable between the vaccine samples and positive control (Fig.1C) .
We also performed a second analysis of antibody titers, based on the ratio of the optical density (OD) of vaccine samples divided by the OD of the positive control ( Fig.1D-F) . This analysis allowed a direct comparison of antibody titers in the vaccinees with titers in patients with natural DENV infection, which we had studied previously (12). After natural secondary infections, an OD ratio > 1 (i.e., an OD value similar or higher than the positive control) was observed within the first three months of infection, before a gradual reduction to a ratio of approximately 0.5 after one year. However, in the majority of the vaccine samples studied here, the OD ratio was below 0.1 and not higher than the negative control ( Fig.1D-F ).
We hypothesized that the higher titers of antibodies to UV-DENV and E protein observed in some participants ( Fig.1A -C) may be related to pre-existing dengue immunity at the time of vaccination.
Screening was only performed in a subset of study participants prior to the start of the original clinical trial; therefore, this information was only available for 9 out of 23 participants (Table 1) . Unexpectedly, antibody titers did not correlate with immune status at vaccination (Fig.2) , but a larger sample number would be required to confirm this finding. Unfortunately, pre-existing titers were not known for participants DV-19 and DV-20, both of which showed high antibody titers in this study. 
Plasma antibodies in vaccinees show limited in vivo efficacy against DENV-2
Although the readouts from the ELISAs provide information about the relative amounts of antibodies present against different epitopes, the protective efficacy of those antibodies is unknown. Similarly, poor correlations between neutralizing titers, determined by neutralization assay, and in vivo efficacy have been reported previously (7, 18) . Mouse models offer a valuable method to determine the neutralizing capacity of human plasma antibodies in vivo (19, 20) . We tested the neutralizing capacity of DENVspecific antibodies from the vaccinees by transferring plasma (100 µl) into interferon alpha/beta and gamma-receptor (IFNAGR)-deficient mice, and challenging with DENV-2 after 24 hours (Fig.3A) . IFNAGR mice were selected for this experiment because wild-type mice are not susceptible to dengue infection (21) . The DENV-2 serotype was selected because it results in a high and reproducible viremia in mice, compared with the other serotypes. Viral loads were measured in the blood of infected mice at the peak of viremia three days after infection. Plasma from a recovered patient who had experienced secondary DENV-2 infection four months earlier was used as a positive control (12) (Fig.3B) . In a separate experiment, we also tested the positive control plasma used in the ELISAs as well as samples from two patients with DENV-2 infection one year earlier (12). All control samples reduced viremia in mice more Downloaded by [155.69. 16 .255] at 18:53 18 February 2016 9 than 100-fold (Fig.3C) . In contrast, only 2 out of 23 vaccinee plasma samples reduced viremia by more than ten times (Fig.3B) . These two samples, DV-19 and DV-20, were the same as those that showed high titers in both the UV-DENV and the E protein ELISA. However, we did not observe a significant correlation between viremia and either DENV-2 UV-DENV or E titers, most likely because of the comparatively low titers of the remaining samples (Fig.3D ). To address a potential correlation of in vivo efficacy with neutralizing titers, we determined the 50% focus reduction neutralization test (FRNT50) titers for all samples and the ELISA positive control (Fig.3E ). In line with the ELISA data, samples DV-19 and DV-20 had substantially higher titers than all other samples and the positive control. The in vivo experiments suggested that relatively high antibody titers were required to achieve significant antibodymediated reduction of viremia. Samples DV-19 and DV-20 showed titers of > 48,000 for DENV-2 in the E protein ELISA, titers of 5,400 for DENV-2 in the UV-DENV ELISA, and titers > 640 in the FRNT assay.
Interestingly, samples DV-19 and DV-20 were also the only two samples with DENV-2 EDIII titers higher than the negative control (Fig.1D) . With the limited number of samples analyzed here, it was not possible to conclude whether E protein-specific, EDIII-specific, and/or virus particle-specific antibodies were responsible for the in vivo efficacy. While pre-existing antibodies in the plasma, as detected in the previous assays, are crucial for early virus neutralization, the rapid activation of pre-existing immune memory cells also contributes to protection after secondary infection (22) . We performed ELISPOT assays to quantify the numbers of specific memory B cells present in vaccinee samples by re-stimulating PBMCs with Protein A, CpG, and IL-21 on ELISPOT plates coated with virus particles (23) or tetanus toxoid (24) (Fig.4) . The efficiency of restimulation varied between samples (Fig.4A ), but the number of DENV-specific memory B cells per total IgG-secreting antibody-secreting cells (ASC) was typically below 0.5% (Fig.4B) . Tetanus-specific immunity could be detected in 17 out of 20 samples tested and, in one particular sample, represented > 2% of total memory B cells (Fig.4C) . Interestingly, DENV-specific B cell spots were generally small, compared to tetanus-specific B cells, which generated larger spots (Fig.4D ), indicating that a low amount of antibodies was secreted per DENV-specific B cell. Percentages of specific cells for DV-20 to DV-23 could not be calculated because total IgG ASC numbers were not available for these samples, but DENVspecific memory B cells were only detected in DV-22. 
Discussion
The CYD-TDV live-attenuated dengue vaccine candidate has been tested recently in large efficacy trials (2) (3) (4) (5) . While the efficacy of the vaccine is now established, few data are available on the long-term immune memory generated by this vaccine (6) . Such data are essential to decide if and when revaccination might be required. Because the vaccine is more efficacious in individuals with pre-existing DENV immunity (plaque reduction neutralizing titers (PRNT50) of > 10) from previous DENV or related flavivirus infections, it can be assumed that protection relies on the expansion of pre-existing crossreactive immune memory (3, 4) . It is well established that such cross-reactive protection is temporary, lasting two years at best (14-16). Re-vaccination with the CYD-TDV vaccine might therefore be required to maintain sufficient levels of protective immunity.
The in vivo protection model used here provides a functional readout to assess the efficacy of antibodies generated after vaccination. Pre-existing antibodies in the blood at the time of infection are crucial to reduce the initial viral load and can be sufficient for protection (25) . Within a few days of infection, memory B and T cells, which are activated, expanded, and differentiated, begin to produce high amounts of antibodies and "kill" infected cells, respectively, further decreasing the viral load (10, 23, (26) (27) (28) (29) (30) . The plasma transfer model specifically addresses the role of pre-existing antibodies, and not memory lymphocytes. Our findings suggest that relatively high pre-existing antibody titers are required for a The low antibody titers and limited in vivo efficacy of plasma transfer suggest that five years after vaccination with CYD-TDV, immunity to DENV mediated by pre-existing antibodies is largely lost. While the in vivo protection model presented here needs to be further validated and compared to ELISA and neutralization readouts, the data suggest that to be protective, immunity to dengue needs to be sustained over time with antibody titers above a certain level at the time point of infection.
Methods
Human samples 
ELISA
ELISAs were conducted as described previously (12). In brief, half-area plates (Greiner) were coated with PEG-precipitated virus particle, recombinant E protein, or recombinant EDIII of DENV serotypes 1-4. The following DENV strains isolated from patients were used for virus particle ELISAs: DENV1-08K3126 (unpublished genotype I strain isolated by the Environmental Health Institute, Singapore), DENV2-TSV01 (AY037116.1), DENV3-VN32/96 (EU482459), and DENV4-2641Y08 (HQ875339.1). The soluble domains of E proteins and the EDIII of DENV1-4 were produced in S2 cells with a His-tag and were purified using Ni-beads. The following strains were used for the construction of E and EDIII: DENV1-05K2916 (EU081234), DENV2-TSV01 (AY037116.1), DENV-3 05K4141 (EU081214.1), and DENV4-2641Y08 (HQ875339.1). Recombinant proteins were coated at 75 ng/well. For all ELISAs, plates were blocked with PBS, 0.05% Tween 20 (PBST) containing 3% skimmed milk. Plasma samples and the positive control were diluted in blocking buffer before being transferred to the coated plates. For the positive control, we pooled three plasma samples out of eight tested based on a high OD value against all four serotypes in the UV-DENV ELISA. For the negative control, three plasma samples without dengue immunity were pooled. Anti-human IgG-HRP (Sigma) was added at a concentration of 1:2000. 3,3,5,5-tetramethylbenzidine HRP substrate solution (Sigma) was used for color development and the reactions were stopped with 1M HCl. The endpoint titer was defined as the lowest OD450 value that was higher Downloaded by [155.69. 16 .255] at 18:53 18 February 2016 than two times the background. For OD ratios, sample ODs at a 1:600 dilution were divided by the OD of the positive control at a 1:600 dilution on the same plate.
ELISPOT PBMC from 9 ml whole blood were isolated using BD Vacutainer CPT Sodium Citrate tubes. Plasma (top layer) was collected for ELISA. The PBMC layer was collected and washed twice with 1× PBS before resuspending cells in RPMI containing 10% FCS and Penicillin/Streptomycin. PBMCs (2.5 × 10 6 in 2.5 ml medium) were added to 6-well plates (Thermo Scientific). The B cell stimulation cocktail (final concentration of 6 µg/ml CpG, 1/10,000 dilution of Staphylococcus Aureus Cowan (Sigma), 50 ng/ml IL-21 (Immunotools)) was added to each well. For the non-stimulated control, PBMCs (0.5 × 10 6 in 0.5 ml)
were incubated in a 48-well plate (Thermo Scientific). Supernatant and cells were collected on day 6. 
In vivo protection assay
Female or male 6-to 8-week-old IFN-α/β/γ receptor-deficient mice (AG129) were purchased from B&K Universal Limited. Mice were intraperitoneally (i.p.) administered 100 μl filtered (0.22 μm) human plasma.
Decrease of viremia after transfer of 100 or 200 μl of plasma, as tested in n=3 mice/group (data not shown), was not significantly different; therefore we chose the smaller amount (100 μl) for our experiments. After 24 h, mice were subcutaneously infected with 200 µl of 2.7 × 10 7 PFU/ml DENV-2 TSV01. After a further 72 h, blood was collected by retro-orbital bleeding and plasma was kept at ˗80°C until analysis. Viremia was quantified by RT-PCR as described previously with slight modification in primers (35) . RNA was isolated from 70 µl of plasma and a standard virus sample with known pfu/ml was used in all assays for quantification (36) . IFN-α/β/γ receptor-deficient AG129 mice backcrossed to the C57BL/6 background were used to test the samples shown in Figure 3C . All mice were bred and kept under specific-pathogen-free conditions at the Biomedical Resource Centre, Singapore. 
